Searched for
FDA APPROVAL ALHEMO
Is Novo Nordisk facing its “Nokia moment”? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forcesNovo Nordisk’s stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, and legal ch...- European shares dip at the open; Novo Nordisk jumpsEuropean stocks opened lower, mirroring last week's decline, with travel and media sectors lagging. Novo Nordisk rebounded after Friday's l...
- Load More